Everest balances local, international offerings in IPO that could be biggest yet on Hong Kong biotech chapter
Mainland China biotech raises $451M for a valuation of over $2B
Led by CEO Kerry Blanchard, mainland China biotech Everest Medicines raises $451 million in a deal that gave it a valuation of more than $2 billion.
Oct 9, 2020 | 1:31 AM GMT
Strong local demand allowed Everest to price